Madrid, 22nd April, 2008.- Cellerix, a biopharmaceutical company that develops and produces innovative medicines based on cellular therapy, has appointed Miguel Fenoy to its team as Director of Clinical Operations.

Miguel Fenoy has a degree in Business Administration from the University of Cologne (Germany). He speaks four languages.

Fenoy has 15 years of experience in the international pharmaceutical industry, both in the sector of Contract Research Organizations or CROs (Parexel) and in different pharmaceutical companies (Pharmacia Corp in France, Pfizer in France, Pharmacia & Upjohn in Italy), where he worked as Project Manager in various therapeutic areas, such as oncology and gastroenterology.

In addition, he has extensive experience coordinating clinical tests in each of the different phases of development, including multidisciplinary team management, regulatory affairs, program design and development, CRO selection and business resource planning.

Previously, Fenoy was the Associate Director of Clinical Tests at PDL BioPharma, where for four years he was in charge of projects in Gastroenterology and focused on the company’s European activities.

In his new job, Miguel Fenoy will be responsible for carrying out all the multinational clinical tests for the company, using its own resources or working through specialized external suppliers.

Notes to editors

Cellerix is a biopharmaceutical company developing innovative medicines based on cell therapy. The company has two products undergoing clinical trials: Cx401 for the treatment of perianal fistulas, currently in Phase III, and Cx501 for skin regeneration, currently in Phase II. Cx401 and Cx501 have orphan status by the European Medicines Agency (EMEA). Cellerix closed in September 2007 a €27.2 million financing round led by international venture capital companies. In October 2007 it entered into an exclusive license and development agreement with Axcan Pharma for the North American rights to Cx401.